Mark N Stein

Summary

Affiliation: New Jersey
Country: USA

Publications

  1. ncbi request reprint CCR drug updates: sorafenib and sunitinib in renal cell carcinoma
    Mark N Stein
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA
    Clin Cancer Res 13:3765-70. 2007
  2. pmc Transdermal estradiol in castrate and chemotherapy resistant prostate cancer
    Mark Stein
    The Cancer Institute of New Jersey, UMDNJ RWJMS, New Brunswick, NJ 08901, USA
    Med Sci Monit 18:CR260-4. 2012
  3. pmc A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
    Robert S DiPaola
    Department of Medicine, The Cancer Institute of New Jersey, UMDNJ RWJMS, New Brunswick NJ, USA
    J Transl Med 8:20. 2010
  4. pmc Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies
    Mark Stein
    Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08901, USA
    Prostate 70:1388-94. 2010
  5. doi request reprint Patterns and correlates of prostate cancer treatment in older men
    Calpurnyia B Roberts
    Department of Medicine, State University of New York Downstate Medical Center, Brooklyn, NY, USA
    Am J Med 124:235-43. 2011
  6. pmc Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml
    Yu Hsuan Shao
    Dean and Betty Gallo Prostate Cancer Center, Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, USA
    Arch Intern Med 170:1256-61. 2010
  7. ncbi request reprint A phase II study of atorvastatin and celecoxib in patients with rising PSA following local therapy for prostate cancer (PC)
    Susan Goodin
    Cancer Institute of New Jersey, New Brunswick, NJ Rutgers University, Piscataway, NJ Cooper Cancer Institute, Voorhees, NJ Wayne State University Karmanos Cancer Center, Detroit, MI
    J Clin Oncol 30:89. 2012
  8. doi request reprint Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors
    Antoinette R Tan
    The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA
    Cancer Chemother Pharmacol 71:1635-43. 2013
  9. doi request reprint A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors
    Luis E Raez
    Department of Medicine, Division of Hematology Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, PO Box 016960, Miami, FL 33101, USA
    Cancer Chemother Pharmacol 71:523-30. 2013
  10. pmc Abiraterone in prostate cancer: a new angle to an old problem
    Mark N Stein
    Cancer Institute of NewJersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA
    Clin Cancer Res 18:1848-54. 2012

Collaborators

Detail Information

Publications18

  1. ncbi request reprint CCR drug updates: sorafenib and sunitinib in renal cell carcinoma
    Mark N Stein
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA
    Clin Cancer Res 13:3765-70. 2007
  2. pmc Transdermal estradiol in castrate and chemotherapy resistant prostate cancer
    Mark Stein
    The Cancer Institute of New Jersey, UMDNJ RWJMS, New Brunswick, NJ 08901, USA
    Med Sci Monit 18:CR260-4. 2012
    ....
  3. pmc A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
    Robert S DiPaola
    Department of Medicine, The Cancer Institute of New Jersey, UMDNJ RWJMS, New Brunswick NJ, USA
    J Transl Med 8:20. 2010
    ....
  4. pmc Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies
    Mark Stein
    Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08901, USA
    Prostate 70:1388-94. 2010
    ....
  5. doi request reprint Patterns and correlates of prostate cancer treatment in older men
    Calpurnyia B Roberts
    Department of Medicine, State University of New York Downstate Medical Center, Brooklyn, NY, USA
    Am J Med 124:235-43. 2011
    ..Although elderly men, particularly patients with low-risk prostate cancer and a life expectancy less than 10 years, are unlikely to benefit from prostate cancer active therapy, treatment rates in this group are high...
  6. pmc Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml
    Yu Hsuan Shao
    Dean and Betty Gallo Prostate Cancer Center, Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, USA
    Arch Intern Med 170:1256-61. 2010
    ..Despite controversy over the benefit of prostate-specific antigen (PSA) screening, little is known about risk profiles and treatment patterns in men diagnosed as having prostate cancer who have a PSA value less than or equal to 4.0 ng/mL...
  7. ncbi request reprint A phase II study of atorvastatin and celecoxib in patients with rising PSA following local therapy for prostate cancer (PC)
    Susan Goodin
    Cancer Institute of New Jersey, New Brunswick, NJ Rutgers University, Piscataway, NJ Cooper Cancer Institute, Voorhees, NJ Wayne State University Karmanos Cancer Center, Detroit, MI
    J Clin Oncol 30:89. 2012
    ....
  8. doi request reprint Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors
    Antoinette R Tan
    The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA
    Cancer Chemother Pharmacol 71:1635-43. 2013
    ..This study evaluated the effect of a potent CYP3A4 inhibitor, ketoconazole, and the proton pump inhibitor esomeprazole on the pharmacokinetics and safety of pazopanib and its metabolites...
  9. doi request reprint A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors
    Luis E Raez
    Department of Medicine, Division of Hematology Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, PO Box 016960, Miami, FL 33101, USA
    Cancer Chemother Pharmacol 71:523-30. 2013
    ..This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-D-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors...
  10. pmc Abiraterone in prostate cancer: a new angle to an old problem
    Mark N Stein
    Cancer Institute of NewJersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA
    Clin Cancer Res 18:1848-54. 2012
    ..These promising results now pose a new angle to an old problem about hormonal therapy and raise new questions about how resistance develops, how to best sequence therapy, and how to optimize combinations with other emerging novel agents...
  11. pmc Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors
    Biren Saraiya
    The Cancer Institute of New Jersey, UMDNJ Robert Wood Johnson Medical School, 195 Little Albany St, New Brunswick, NJ 08901, USA
    Invest New Drugs 30:258-65. 2012
    ..In a phase I study, the combination of gemcitabine and imatinib was well tolerated with broad anticancer activity. This phase I trial evaluated the triplet of docetaxel, gemcitabine and imatinib...
  12. pmc Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy
    Robert S DiPaola
    Department of Medicine, University of Medicine and Dentistry of New Jersey UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
    Prostate 68:1743-52. 2008
    ..The understanding of autophagy, as either a mechanism of resistance to therapies that induce metabolic stress, or as a means to cell death, is rapidly expanding and supportive of a new paradigm of therapeutic starvation...
  13. ncbi request reprint A randomized phase II study of bicalutamide (BIC) followed by placebo or gamma secretase inhibitor RO4929097 (RO492) in men with rising PSA
    Mark N Stein
    Cancer Institute of New Jersey, New Brunswick, NJ National Cancer Institute, Bethesda, MD
    J Clin Oncol 30:219. 2012
    ..Serum is collected for evaluation of soluble markers of gamma secretase inhibition. 29 pts/arm in randomization phase gives 90% power to detect a decrease in1 yr PFS from 80% to 45% with 5% alpha...
  14. pmc A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies
    Hongxia Lin
    The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    J Pharm Biomed Anal 66:371-5. 2012
    ..The validated assay is accurate, and sensitive with minimum loss and rapid analysis time and suitable for quantification of gossypol for pharmacokinetics evaluation...
  15. pmc Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach
    Janice M Mehnert
    Department of Medicine, Division of Medical Oncology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey, USA
    Mol Cancer Ther 10:1509-19. 2011
    ....
  16. pmc Contemporary risk profile of prostate cancer in the United States
    Yu Hsuan Shao
    Department of Population Science, Cancer Institute of New Jersey, New Brunswick, NJ, USA
    J Natl Cancer Inst 101:1280-3. 2009
    ..In conclusion, more men were diagnosed with prostate cancer at a younger age and earlier stage in 2004-2005 than in earlier years. The racial disparity in cancer stage at diagnosis has decreased statistically significantly over time...
  17. pmc Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers
    Kim M Hirshfield
    Division of Medical Oncology, Department of Medicine, Rutgers Cancer Institute of New Jersey Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
    Oncologist . 2016
    ..The frequency with which targeted tumor sequencing results will lead to implemented change in care is unclear. Prospective assessment of the feasibility and limitations of using genomic sequencing is critically important...
  18. pmc Identification of the DNA repair defects in a case of Dubowitz syndrome
    Jingyin Yue
    The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States of America
    PLoS ONE 8:e54389. 2013
    ..These data suggests that at least subset of Dubowitz syndrome can be attributed to DNA ligase IV mutations...